Documentos de Académico
Documentos de Profesional
Documentos de Cultura
ENDOMETRIAL CARCINOMA
Index
2. Screening
2.1 Family history - Lynch type 2 syndrome
3. Referral pathway
3.1 For GP
3.2 For non-oncological consultants/ firms
3.3 For referral from unit to centre
4. Diagnosis
5. Investigations
7. Pathology
7.1 Endometrial carcinoma classification (adapted from WHO classification)
7.2 Architectural grading of endometrioid adenocarcinoma (FIGO)
7.3 Nuclear grading
7.4 Type 1 and type 2 tumours
7.4.1 Type 1 carcinoma
7.4.2 Type 2 carcinoma
7.4.3 Overall outcome for endometrial carcinoma based on pathology
7.5 Pathological reporting of endometrial carcinoma
8. Staging
10. Treatment
10.1 Abdominal, vaginal and laparoscopic hysterectomy
10.2 Pelvic lymphadenectomy
10.3 Indications for adjuvant radiotherapy for stage I disease
10.4 Further indications for radiotherapy
10.5 Management of stage II/III disease
10.6 Chemotherapy / progestogens and HRT
10.7 Uterine sarcomas/ carcinosarcomas
12. Survival
12.1 Cancer dataset/ inventory of active trials
13. Follow up
13.1 Identification and management of late effects of treatment
16. Algorithm
17. Summary
18. References
Introduction
Currently about 3900 new cases are diagnosed annually in England and Wales with 770 deaths. This
survival is disappointing considering 75% of patients present with early (stage I) disease, and reflects
the need to develop central referral and the application of All Wales Guidelines (CSCG, 2001).
In Wales, endometrial carcinoma accounts for nearly 4% of all female cancer registrations (1993-
2002) with the highest age-standardised incidence in Anglesey and the lowest in Cardiff. The overall
incidence in Wales is 13.5/100,000 women (WCISU, 1991-1999). The one-year relative survival
increased from 88% for the period 1990-1994 to 92% for the period 1995-1999. A similar
improvement was noted in the five-year relative survival from 75% to 80%.
Endometrial carcinoma is a disease of postmenopausal women with only 25% presenting before the
menopause. Only 2-5% is diagnosed before the age of 40 years. The mean age is 60 years with a peak
incidence between 55 and 70 years.
Risk factors include:
obesity
nulliparity
polycystic ovary syndrome
diabetes
hypertension
family history of endometrial, ovarian or intestinal malignancy
past history of breast, ovarian or intestinal malignancy.
2. Screening
There is no screening programme to detect endometrial carcinoma.
3.1 For GP
If endometrial cancer is suspected then referral should be to a general gynaecologist, the lead in the
cancer unit or gynaecological oncologist in the cancer centre.
Standards
Rapid access to the specialist should be available with the patient seen within 2
weeks of date of receipt of the referral letter/ fax.
Definitive treatment should be commenced no later than 62 days after receipt of the
referral letter/ fax.
Definitive treatment should be commenced no later than 31 days after diagnosis for
non urgent suspect cancer referrals.
If the diagnosis is suspected or confirmed referral to the local unit lead or gynaecological cancer
centre should be made.
4. Diagnosis
Primary assessment in all cases is with transvaginal ultrasound (Karlsson et al, 1995) and pelvic
examination. This strategy also appears to the most cost effective (Clark et al, 2006). All
postmenopausal patients with an endometrial thickness >5mm or persistent bleeding despite a normal
endometrial thickness should have an endometrial biopsy (NHS Executive, 1999; grade B
recommendation). If there is difficulty in obtaining a pelvic scan then an endometrial sample should
be attempted in clinic. If the endometrium is difficult to identify then hysteroscopy should also be
considered. The value of endometrial thickness in perimenopausal bleeding is questionable as the
thickness range is variable. Cervical cytology will detect endometrial carcinoma in only 40% of cases
and is far too unreliable.
Hysteroscopy can be performed in an outpatient setting. It can enable visualisation of the degree of
encroachment of the tumour to the internal os which may then modify the form of treatment offered
(see 15. Algorithm for postmenopausal bleeding ).
5. Investigations
After confirming the diagnosis the objectives of further investigations are to
determine the extent of disease
determine suitability for treatment.
Those that penetrate more deeply into the myometrium are more likely to have involved pelvic nodes.
The frequency of pelvic and para-aortic node involvement increases to 25 and 17% respectively for
deep muscle invasion (Creasman et al, 1987).
A chest X-ray is essential. An MR scan will help identify the site and size of the primary tumour, any
evident myometrial invasion (Kim et al, 1995; Yamashita et al, 1993), the presence of lymph node
metastases and the presence of occult cervical involvement but image resolution of the myometrium
can be disturbed by a recently performed uterine curettage. MR scanning should be considered for all
patients with endometrial cancer prior to treatment (grade B recommendation). Ultrasound can be
used as an alternative but is less accurate than MR. CT scanning is less accurate than both ultrasound
and MR for measuring myometrial infiltration but is an alternative method of imaging extra uterine
disease if a patient is unsuitable for MR.
6.1 Information
Standards
All patients must have access to a gynaecological oncology clinical nurse specialist
within 24 hours of the patient being informed of her diagnosis (this should include
a daytime contact telephone number for the clinical nurse specialist). Preferably the
nurse specialist should be at the consultation when the patient is given her
diagnosis.
All patients must be given appropriate literature about the management, treatment
and outcome for cervical cancer such as a Cancerbackup leaflet or equivalent.
7. Pathology
Endometrioid
Villoglandular
Secretory
Ciliated cell with squamous metaplasia
Endometrioid with squamous differentiation
Serous
Clear cell
Mucinous
Squamous
Mixed types
Undifferentiated
It is important to avoid areas with squamous differentiation and evaluate only glandular areas.
Patients with grade I endometrioid carcinoma and with tumour confined to the endometrium and
without vascular invasion, have an approximately 95% or greater 5 years survival disease-free,
whereas patients with grade III tumours and involvement to the middle third of the myometrium,
together with vessel involvement, have a 5 year disease free survival of approximately 65%.
Statistical models to predict survival are the best method of assessing relative risk. In general, as
most endometrioid carcinomas tend to be low stage and low grade, survival is high. The outcome for
type 2 carcinomas is very different. These patients tend to be considerably older than those with
endometrioid carcinoma and are often high stage at the time of presentation. Under-staging clinically
is common. Five and 10 year survival rates for all stages are approximately 36% and less than 20%.
Some studies even for pathological stage I serous carcinomas have revealed 5 year survival of no more
than 40%. With type 2 tumours prognostic factors indicative of shorter survival include increasing
age, vessel invasion and greater than half the myometrial depth involved. Even intraendometrial
carcinomas have a high risk of metastasis, with 13% of carcinomas confined to the endometrium
having para-aortic lymph node metastases and some studies suggest an outcome even for stage Ia
tumours of only 57% survival at 5 years. Endometrial carcinomas containing a component of serous
carcinoma, making up as little as 25% of the tumour, appear to have the same survival as pure serous
carcinomas.
8. Staging
*The presence of bullous oedema is not sufficient evidence to classify a tumour as T4.
FIGO, 2003
Regional lymph nodes (N) Distant Metastasis (M)
Gross description
Dimensions of uterus: Length ..........mm Transverse .......mm Antero-posterior........mm
Histology
Type: Endometrioid Serous Clear cell
MMMT other (please specify)
Comments
SNOMED Codes
T82000 Uterus (endometrium) M81403 (Adenocarcinoma) M84413(Serous adenocarcinoma)
M83103 (Clear cell carcinoma) M89503 (Mixed Mllerian tumour)
T08000 Lymph node M81406 (Metastatic carcinoma)
women from 1988-2001 has shown that adjuvant radiotherapy after hysterectomy improved overall
and relative survival in stage Ic well and poorly differentiated tumours (Lee et al, 2006). The lack of a
survival advantage for moderately differentiated tumours may have been due to insufficient size of this
cohort of patients.
All cases must be discussed at the gynae cancer MDT to decide further treatment.
Standards
Radiotherapy should start 14 days after referral for radical treatment (good
practice) although 28 days is acceptable (minimum standard).
Radiotherapy should start 28 days after referral for adjuvant treatment (minimum
standard).
JCCO/RCR guidance
External beam / brachytherapy should be given to all stage II patients unsuspected at laparotomy.
Bilateral pelvic lymphadenectomy and radiotherapy may improve local control for node positive
women but additional morbidity (particularly small bowel and ureteric obstruction) must be
considered (Mariani et al, 2006; grade B recommendation). Radiotherapy should be considered for
stage II patients treated with radical hysterectomy if nodes are subsequently found to be involved (re-
staged IIIc).
Patients with stage III and IV disease should be treated with brachytherapy and external beam therapy.
This should be used for stage I and II patients where surgery is contraindicated. Patients with uterine
serosal disease (stage IIIa) and positive peritoneal washings may indicate risk of peritoneal
carcinomatosis and adjuvant chemotherapy could be considered with or without pelvic radiotherapy.
To refer for radical radiotherapy at YGC. Brachytherapy provided by the Christie Hospital in
Manchester.
All cases must be discussed at the gynae cancer MDT to decide further treatment.
low dose progestin (grade C recommendation). Cases should be managed on an individual basis and
patients deserve a comprehensive explanation balancing any potential risks with benefits.
To refer for radical radiotherapy at YGC. Brachytherapy provided by the Christie Hospital in
Manchester. Chemotherapy provided at all 3 North Wales Trusts.
All cases must be discussed at the gynae cancer MDT to decide further treatment.
12. Survival
Patients over 59 years of age at diagnosis may have poorer survival than younger patients (Frick et al.,
1973) and may partly be explained by the increase of poorly differentiated adenocarcinomas,
adenosquamous and clear cell adenocarcinomas in this age group.
Stage I 77%
Stage II 48%
Stage III 34%
Stage IV 7%
Frick et al, (1973); Morrow et al, (1973); Berman et al, (1980); Kauppila et al, (1982); Connelly et
al, (1982).
Seventy four percent of patients present with stage I disease. Overall 5 year survival varies from
66 - 77%.
13. Follow up
The value of clinical follow up is debatable. There is no evidence that an earlier detection of
recurrence leads to an improved survival. However careful inspection and palpation of the vaginal
vault and palpation for any pelvic masses should be performed 3 monthly for 2 years, 6 monthly for 1
year and then annually.
Hospital follow up should be for 5 years. Vaginal vault cytology is not helpful.
All patients must be encouraged to report any symptoms suggestive of recurrent disease immediately
by contacting their CNS rather than wait until their next outpatient appointment.
Postmenopausal
bleeding
USC (see within 2 weeks of referral)
TV USS
endometrial
thickness
Biopsy normal
Endometrial
carcinoma
algorithm (see 16) MDT
*other pathology excluded from this algorithm (such as atypical hyperplasia and endometrial polyps).
In the presence of recurrent bleeding hysteroscopy and biopsy is appropriate.
16. Algorithm
Algorithm for management of patients with endometrial cancer
Stage I Pre-Op
Biopsy
Cancer Unit Hysteroscopy Cancer
or Centre MR scan/ CXR Centre only
MDT
<50% myo >50%myo
G I/ II all G III/ all type 2
ERT if ERT if
G I/II >50% myo Node positive
G III or Type 2 Ib or greater
Stage II
Diagnosed after surgery Diagnosed pre surgery
or unfit and fit
Stage III/IV
ERT/ Surgical debulking and chemotherapy decided on case by case basis
17. Summary
Pre-op assessment
TVS - if postmenopausal for endometrial thickness/ assess adnexae
Biopsy +/- hysteroscopy - if ET >5mm/ repeat referral
Hb, U+E, liver function tests, consider 2 unit cross match
chest X-ray
MR scan abdomen/ pelvis
Surgery
Low risk endometrial cancer (stage I; well/ moderately differentiated
adenocarcinoma, <1/2 thickness myometrial invasion and no lymph
node metastases on MR scanning) - TAH/BSO/washings/omental
biopsy.
High risk endometrial cancer (stage I; poorly differentiated,
adenosquamous, clear cell or serous papillary carcinoma, or well/
moderately differentiated >1/2 thickness myometrial invasion) -
TAH/BSO/washings/omental biopsy/pelvic lymphadenectomy if patient
suitable for prolonged surgery.
Consider laparoscopic or vaginal hysterectomy.
Stage II disease - radical (Wertheim) hysterectomy/pelvic
lymphadenctomy.
Post radiation isolated central pelvic recurrence - anterior/ posterior
exenteration.
Isolated vaginal recurrence consider surgical excision/radiotherapy.
18. References
Aalders J, Abler V, Kolstad P et al. (1980) Postoperative external irradiation and prognostic
parameters in stage I endometrial carcinoma: clinical and histopathological study of 540 patients.
Obstet Gynecol, 56, 419-27.
Berman ML, Barlow SC, Lagasse LD et al. (1980) Prognosis and treatment of endometrial
cancer. Am J Obstet Gynecol, 136, 679.
Chan JK, Cheung MK, Huh WK et al. (2006) Therapeutic role of lymph node resection in
endometrioid corpus cancer. Cancer, 107, 1823-30.
Clark TJ, Barton PM, Coomarasamy A et al. (2006) Investigating postmenopausal bleeding for
endometrial cancer: cost-effectiveness of initial diagnostic strategies. Br J Obstet Gynaecol, 113,
502-10.
Connelly PJ, Alberhashy RC, Christopherson WM (1982) Carcinoma of the endometrium III.
Analysis of 865 cases of adenocarcinoma and adeno-acanthoma. Obstet Gynecol, 59, 569.
COSA-NZ-UK Endometrial cancer study groups. (1996) Pelvic lymphadenectomy in high risk
endometrial cancer. Int J Gynecol Cancer, 6, 102-7.
Creasman WT, Boronow RC, Morrow CP et al. (1976) Adenocarcinoma of the endometrium: Its
metastatic lymph node potential. Gynecol Oncol, 4, 239
Creutzberg CL, van Putten WL, Koper PC et al. (2000) Surgery and postoperative radiotherapy
versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised
trial. PORTEC Study Group. Lancet; 35, 1404-11.
Creutzberg CL, van Putten WLJ, Koper PC et al. (2003) Survival after relapse in patients with
endometrial cancer: results from a randomised trial. Gynecol Oncol; 89, 201-9.
Frick HC II, Munnell EW, Richart RM et al. (1973) Carcinoma of the endometrium. Am J Obstet
Gynecol, 115, 663.
Humber CE, Tierney JF, Symonds RP et al. (2007) Chemotherapy for advanced, recurrent or
metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol. 18,
409-20.
Irwin C, Levin W, Fyles A et al. (1998) The role of adjuvant radiotherapy in carcinoma of the
endometrium - results in 550 patients with pathologic stage I disease. Gynecol Oncol, 70, 247-
54.
Kelley RM, Baker WH (1961) Progestational agents in the treatment of carcinoma of the
endometrium. N Eng J Med, 264, 216.
Kim SH, Kim HD, Song YS et al. (1995) Detection of deep myometrial invasion in endometrial
carcinoma: comparison of transvaginal ultrasound, CT, and MRI. J Comput Assist Tomogr, 19,
766-72.
Lawton F. (1997) The management of endometrial cancer. Br J Obstet Gynaecol, 104, 127-34.
Lee CM, Szabo A, Shrieve DC et al. (2006) Frequency and effect of adjuvant radiation therapy
among women with stage I endometrial adenocarcinoma. JAMA, 295, 389-97.
Leveque J, Goyat F, Dugast J et al. (1998) Value of peritoneal cytology after hysteroscopy in
surgical stage I adenocarcinoma of the endometrium. Oncol Rep, 5, 713-5.
Lovecchio JL, Averette HE, Lichtinger M et al. (1984) Treatment of advanced or recurrent
endometrial adenocarcinoma with cyclophosphamide, doxorubicin, cis-Platinum and megestrol
acetate. Obstet Gynecol, 63, 557.
MacDonald RR, Thorogoog J, Mason MK. (1988) A randomised trial of progestogens in the
primary treatment of endometrial carcinoma. Br J Obstet Gynaecol, 95, 160-74.
Magrina JF, Mutone NF, Weaver AL et al. (1999) Laparoscopic lymphadenectomy and vaginal or
laparoscopic hysterectomy with bilateral salpingo-oophorectomy for endometrial cancer:
morbidity and survival. Am J Obstet Gynecol, 181, 376-81.
Mariani A, Webb MJ, Keeney GL et al. (2000) Low-risk corpus cancer: Is lymphadenectomy or
radiotherapy necessary? Am J Obstet Gynecol, 182, 1506-19.
Mariani A, Webb MJ, Keeney GL et al. (2001) Role of wide/ radical hysterectomy and pelvic
node dissection in endometrial cancer with cervical involvement. Gynecol Oncol, 83, 72-80.
Mariani A, Dowdy SC, Cliby WA et al. (2006) Efficacy of systematic lymphadenectomy and
adjuvant radiotherapy in node-positive endometrial cancer patients. Gynecol Oncol, 101, 200-8.
Morrow CP, DiSaia PJ, Townsend DE. (1973) Current management of endometrial carcinoma.
Obstet Gynecol, 42, 339.
Morrow CP, Bundy BN, Kurman RJ et al. (1991) Relationship between surgical-pathological risk
factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic
Oncology Group study. Gynecol Oncol, 40, 55-65.
Nelson G, Randall M, Sutton G et al. (1999) FIGO stage IIIc endometrial carcinoma with
metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables,
and failure patterns following adjuvant radiation therapy. Gynecol Oncol, 75, 211-4.
NICE. (2004) Improving Supportive and Palliative Care for Adults with Cancer.
Nieto JJ, Gornall R, Toms E et al. (2002) Influence of omental biopsy on adjuvant treatment field
in clinical stage I endometrial carcinoma. Br J Obstet Gynaecol, 109, 576-8.
Olah KS, Dunn JA, Gee H. (1992) Leiomyosarcomas have a poorer prognosis than mixed
mesodermal tumours when adjusting for known prognostic factors: the result of a retrospective
study of 423 cases of uterine sarcoma. Br J Obstet Gynaecol, 99, 590-4.
Podratz KC, Mariani A, Webb MJ. (1998) Staging and therapeutic value of lymphadenectomy in
endometrial cancer. Gynecol Oncol, 70, 163-4.
Quinn MS, Campbell JJ. (1989) Tamoxifen therapy in advanced/ recurrent endometrial
carcinoma. Gynecol Oncol, 32, 1-3.
Thigpen, T, Blessing J et al. (1993) Phase III trial of doxorubicin +/- cisplatin in advanced or
recurrent endometrial carcinoma: a Gynecologic Oncology Group (GOG) study (abstract). Proc
Am Soc Clin Oncol, 12, 261.
IIa Evidence obtained from at least one well designed controlled study
without randomisation
IIb Evidence obtained from at least one other type of well designed quasi-
experimental study
Grades of recommendation
This guideline has been developed by the North Wales Cancer Centre Guideline Group